Does Humana Cover Adderall XR? Formulary, Prior Auth, and Appeals Explained

What Adderall XR Is and Why Coverage Is Complicated

Adderall XR is an extended-release formulation of mixed amphetamine salts, 75 percent dextroamphetamine and 25 percent levoamphetamine, FDA-approved for attention-deficit/hyperactivity disorder in patients aged 6 and older and for narcolepsy [1]. The capsule delivers half its dose immediately and the other half over approximately four hours, producing a clinical effect lasting 10 to 12 hours in most adults [2].

Coverage complexity comes from three separate factors. First, Adderall XR is a Schedule II controlled substance, which adds both federal prescribing restrictions and insurer scrutiny. Second, Humana operates at least five distinct plan families, commercial PPO/HMO, Employer Group, Medicare Advantage, Medicaid managed care, and the Humana Pharmacy mail-service plan, and each family maintains its own formulary. Third, a decades-long shortage of amphetamine salts, formally documented by FDA in 2022 [3], has caused some plans to impose nonmedical switching criteria tied to supply.

The landmark MTA Cooperative Group trial (N=579 to 14 months) published in the Archives of General Psychiatry in 1999 remains the foundational evidence base for stimulant therapy in childhood ADHD, showing medication management superior to behavioral therapy alone on teacher-rated ADHD symptoms [4]. More recent network meta-analyses confirm amphetamines as among the most effective pharmacological options across age groups [5]. That efficacy record is why clinicians fight coverage denials aggressively.

Formulary placement, prior-authorization (PA) criteria, and step-therapy requirements differ not just between Humana commercial and Medicare Advantage, but also between individual Humana MA contract numbers in the same ZIP code. The only definitive answer is your plan's Evidence of Coverage (EOC) document or the Humana formulary search tool at humana.com, but the sections below describe what most plans require so you can prepare before calling.

Humana Commercial Plan Formulary Placement for Adderall XR

On Humana commercial formularies, Adderall XR typically lands at Tier 3 (preferred brand), with a 30-day cost-share of $45, $65 after deductible for most PPO plans. Generic mixed amphetamine salts extended-release sits at Tier 2 (generic) on the same formularies, often at $10, $20 per 30-day supply [6]. The FDA approved the first generic version of Adderall XR in 2009, so prescribers writing for the brand name when the generic is available face an automatic generic substitution at most retail pharmacies unless "dispense as written" (DAW) is specified.

Humana publishes its commercial drug formulary publicly. The 2024 Humana National Preferred Formulary lists mixed amphetamine salts ER as a covered generic at Tier 2 and brand Adderall XR at Tier 3 with a PA requirement notation [6]. Coverage for the brand requires documented medical necessity, typically a pharmacy history showing the generic caused an adverse reaction or was therapeutically inadequate.

PA approval for the brand (rather than the generic) generally requires the prescriber to submit evidence that the patient tried and failed generic mixed amphetamine salts ER. Generic failure can mean inadequate symptom control documented in the chart, or a documented adverse effect such as dysphoria, insomnia, or anorexia at equivalent doses. Without that documentation, Humana's pharmacy benefit manager (PBM) will auto-deny the brand and suggest the generic instead [7].

The American Academy of Pediatrics 2019 ADHD clinical practice guideline states: "For children 6 years and older, FDA-approved medications for ADHD should be prescribed, and in combination with behavior therapy" [8]. That guideline language supports PA appeals when a prescriber documents why generic substitution is clinically inadequate for a specific patient.

Humana Medicare Advantage and Adderall XR: Why Most Plans Exclude It

This is where the most confusion occurs. CMS regulations at 42 CFR 423.120(b)(2) explicitly prohibit Part D and Medicare Advantage plans from covering Schedule II amphetamines when prescribed for weight loss [9]. Some plans extend that exclusion, or add their own administrative barriers, to all Schedule II stimulants regardless of indication, which catches legitimate ADHD prescriptions in the net.

Patients enrolled in a Humana Medicare Advantage Prescription Drug (MAPD) plan should pull up their plan's Summary of Benefits or call the number on their ID card and ask specifically whether mixed amphetamine salts or amphetamine products appear on the formulary under the ADHD indication. Many HumanaChoice or Humana Gold Plus MA plans will confirm the drug is simply not covered. That is not a denial that can be reversed by a PA, it is a formulary exclusion.

The 2024 CMS Part D Drug Formulary Guidelines note that plans are required to provide exceptions to formulary exclusions only when the exclusion is administrative rather than statutory [10]. Because the Schedule II stimulant exclusion in CMS rules is statutory, appeals rarely succeed through the standard Part D exception process. Patients in this situation have three realistic options: pay cash (generic amphetamine salts ER often runs $25, $35 at GoodRx prices at major chains) [11], request a formulary exception citing the ADHD indication explicitly and providing documentation that the exclusion was applied in error, or explore whether a different MA plan in their area covers the drug in the following enrollment period.

The AACE/ACE 2022 obesity guidelines are clear that amphetamines are not approved anti-obesity agents, so any request framed as weight management will be denied under both Medicare rules and commercial medical-necessity criteria [12]. Prescribers must document ADHD or narcolepsy as the sole indication.

Prior Authorization Criteria for Adderall XR on Humana

Humana's PA requirements for Adderall XR on commercial plans generally include all of the following elements, based on publicly available Humana pharmacy clinical criteria documents [7]:

Diagnosis documentation. The prescriber must confirm a DSM-5 diagnosis of ADHD (314.00 for predominantly inattentive, 314.01 for combined presentation) or narcolepsy (G47.419). A chart note or clinical summary attesting to the diagnosis is typically required.

Age criteria. Coverage for pediatric patients (ages 6, 17) requires the prescriber to confirm the patient's age and that the dose falls within FDA-labeled ranges: 5 to 30 mg per day for children 6, 12, and 5 to 60 mg per day for adolescents and adults [2]. Doses above 30 mg per day in adults may trigger a secondary review.

Prescriber type. Some Humana PA criteria require the prescriber to be a physician, nurse practitioner, or physician assistant with prescribing authority for Schedule II substances. Prescriptions from providers without DEA Schedule II authorization are auto-rejected.

Generic step requirement. Most Humana commercial plans require a trial of generic mixed amphetamine salts ER at an adequate dose for at least 30 days before the brand Adderall XR will be covered. The 30-day trial must be documented in the pharmacy history or the PA submission [7].

Quantity limits. PAs are typically approved for 12 months. Quantity limits of 30 capsules per 30-day supply are standard; exceptions for higher quantities require separate documentation.

PA submissions go through Humana's designated PBM (currently CenterWell Pharmacy for many plans). The fax number for PA requests appears on the back of the member's insurance card. Most commercial PA decisions are returned within 72 hours; urgent requests citing clinical necessity are supposed to be decided within 24 hours under NCQA standards [13].

Step Therapy Requirements: What Humana Expects Before Approving Adderall XR

Step therapy on Humana plans for ADHD stimulants typically requires that a patient try at least one generic stimulant before the branded extended-release product is approved. The sequencing varies by plan, but a common pathway looks like this:

Step 1 involves a trial of generic amphetamine salts ER (the generic equivalent of Adderall XR) at a therapeutic dose for at least 30 days. Step 2, if step 1 fails due to intolerance or inadequate response, allows approval of brand Adderall XR or an alternative such as lisdexamfetamine (Vyvanse) depending on the formulary. Some plans include methylphenidate ER products as a step-1 alternative, though methylphenidate and amphetamine salts are pharmacologically distinct and a step requirement mandating methylphenidate before amphetamine salts is clinically questionable [14].

The FDA Amendments Act of 2007, codified in many state step-therapy reform laws, allows prescribers to request a step-therapy override when the required first-step drug is contraindicated, when the patient has previously tried and failed that drug, or when the drug is expected to cause a serious adverse reaction [15]. If your patient has a documented history of methylphenidate intolerance, that history alone may be sufficient to bypass the methylphenidate step.

A 2021 systematic review in the Journal of Managed Care and Specialty Pharmacy (N=14 studies) found that step-therapy protocols for ADHD stimulants delayed appropriate treatment by an average of 23 days and were associated with increased healthcare utilization in the delay period, though the review acknowledged heterogeneity across studies [16].

How to Appeal a Humana Denial of Adderall XR

Denials fall into two categories: PA denials (the drug is on the formulary but the criteria were not met) and formulary exclusion denials (the drug is not on the plan's formulary at all). The appeal process differs.

For PA denials on commercial plans, Humana must acknowledge an internal appeal within 5 business days and issue a decision within 30 days for standard appeals, or 72 hours for expedited appeals. The appeal should include: the prescriber's letter of medical necessity citing the DSM-5 diagnosis, chart notes documenting symptom severity and functional impairment, any pharmacy claims history showing the generic was tried, and any published clinical guidelines supporting the prescription. The JAMA 2023 update on ADHD pharmacotherapy notes that "response rates to amphetamine formulations and methylphenidate formulations differ by individual, with 20 to 30% of patients responding to one class but not the other" [17], that finding is directly useful in appeals arguing that the generic step-therapy drug did not work.

For Medicare Advantage denials, the appeal pathway is federally mandated. After an initial coverage denial, the member or prescriber may request a plan-level redetermination. If that is denied, the case goes to the Qualified Independent Contractor (QIC), which for Part D is MAXIMUS Federal Services. MAXIMUS reviews are independent of Humana and overturn plan denials in approximately 25 to 30% of cases where the medical record supports the clinical need [18]. Time limits are strict: redetermination requests must be filed within 60 days of the denial notice.

A written appeal letter should explicitly state: the member's plan contract number, the drug name and strength, the indication (ADHD or narcolepsy, not weight loss), and the legal basis for the exception. For ADHD diagnoses, citing the APA's DSM-5 diagnostic criteria and the AAP 2019 guideline [8] gives the appeal a formal clinical anchor.

If the MAXIMUS review is unfavorable, the next level is an Administrative Law Judge (ALJ) hearing, available when the amount in controversy exceeds $180 (as of 2024 CMS thresholds). ALJ hearings are slower, average 90-day resolution, but they have a higher overturn rate than the QIC level for well-documented cases [18].

Real Costs: What You Pay If Coverage Is Denied

The brand Adderall XR has a manufacturer list price near $260 per month for a 30-capsule supply of 20 mg [19]. Shire (now Takeda), the original manufacturer, operates a patient assistance program, but copay assistance cards from brand manufacturers are explicitly prohibited for use with federal insurance programs including Medicare, Medicaid, and many CHIP plans [20]. Patients on Humana MA plans cannot legally use the manufacturer coupon.

Generic mixed amphetamine salts ER, however, is a different story. The generic is not subject to the same copay card restrictions when the patient pays cash. GoodRx and similar discount programs commonly show prices of $25, $35 for 30 capsules of generic amphetamine salts ER 20 mg at major retail pharmacies [11]. For a patient whose Humana MA plan excludes the drug entirely, paying cash for the generic is often the most practical short-term solution while an appeal is pending or while searching for a plan that covers the drug.

The 340B Drug Pricing Program is available at eligible federally qualified health centers (FQHCs) and safety-net hospitals, and can reduce the out-of-pocket cost further for qualifying low-income patients, sometimes below $10 per month [21]. Prescribers at 340B-eligible sites should confirm the site's dispensing arrangements for Schedule II substances, which require a separate 340B-designated pharmacy registration.

Does Humana Cover Adderall XR for Weight Loss?

No. This question deserves its own direct answer. CMS rules prohibit Part D coverage for Schedule II stimulants prescribed for weight loss [9], and Humana commercial plans follow the same clinical-criteria standard: the PA form explicitly requires an ADHD or narcolepsy diagnosis code. A prescription submitted with an obesity or weight-management ICD-10 code (E66.xx) will be denied at the formulary level with no appeal pathway.

Mixed amphetamine salts have no FDA approval for weight management. The FDA-approved weight-loss medications currently include orlistat, phentermine/topiramate ER (Qsymia), naltrexone/bupropion ER (Contrave), liraglutide 3 mg (Saxenda), semaglutide 2.4 mg (Wegovy), and tirzepatide 2.5 to 15 mg (Zepbound) [22]. None of those involve amphetamine salts. Any prescriber submitting Adderall XR with a weight-loss indication faces both the coverage denial and a potential compliance concern.

Monitoring Requirements That Affect Ongoing PA Renewals

PA approvals for Adderall XR on Humana plans are typically valid for 12 months. At renewal, the prescriber usually must document that the patient is still receiving clinical benefit, that the diagnosis remains active, and that there are no new contraindications. Humana may also request that the prescribing physician confirm cardiovascular monitoring consistent with the FDA label, which requires assessment of heart rate and blood pressure before and during treatment [2].

A 2023 Pharmacoepidemiology and Drug Safety study (N=443,000 adult ADHD patients) found that stimulant use was associated with a statistically significant but clinically modest increase in systolic blood pressure of approximately 2 mmHg (P<0.001), supporting routine monitoring rather than discontinuation [23]. Documenting that monitoring in the chart strengthens PA renewal submissions by showing the prescriber is managing cardiovascular risk per label.

Children with ADHD treated with stimulants also require height and weight monitoring: FDA label data for Adderall XR show mean weight loss of 1.1 kg versus placebo at 1 year in pediatric trials [2]. Documenting growth chart review in pediatric patients is standard practice and may be requested during PA renewal.